Abstract
A role for CD20 antibodies in treating prostate cancer has not yet been established. We report a case of advanced prostate cancer presenting with generalized lymphadenopathy that expressed CCR7 and CD20. CCR7 expression in prostate cancer has been previously reported only once; the expression of CD20 has not been reported before. Rituximab therapy was initiated in this case and resulted in a significant biochemical response. This unique metastatic and biochemical pattern may signify a distinct subtype of prostate cancer that may be amenable to treatment with anti-CD20 antibodies.
MeSH terms
-
Adenocarcinoma / blood
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / immunology
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use*
-
Antigens, CD20 / immunology*
-
Antineoplastic Agents / therapeutic use*
-
Humans
-
Kallikreins / blood
-
Lymphatic Diseases / blood
-
Lymphatic Diseases / drug therapy
-
Lymphatic Diseases / immunology
-
Male
-
Middle Aged
-
Prostate-Specific Antigen / blood
-
Prostatic Neoplasms / blood
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / immunology
-
Rituximab
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20
-
Antineoplastic Agents
-
Rituximab
-
KLK3 protein, human
-
Kallikreins
-
Prostate-Specific Antigen